Safety and Effectiveness of JUVÉDERM® VOLUMA® With Lidocaine for Improvement of Volume and Aesthetic Appearance of the Nose in Chinese Adults
- Conditions
- Interventions
- First Posted Date
- 2018-02-13
- Last Posted Date
- 2020-12-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 164
- Registration Number
- NCT03430986
- Locations
- 🇨🇳
Union Hospital Tongji Medical College, Huazhong University of Science and Technology, Beijing, Wuhan, China
🇨🇳Shanghai Sixth People's Hospital, Shanghai, Shanghai, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
Study to Evaluate Botulinum Neurotoxin Serotype E (EB-001) in Reducing Musculoskeletal Pain in Abdominoplasty
- Conditions
- Interventions
- First Posted Date
- 2018-02-12
- Last Posted Date
- 2019-08-05
- Lead Sponsor
- Allergan
- Target Recruit Count
- 23
- Registration Number
- NCT03429556
- Locations
- 🇺🇸
Huntington Ambulatory Surgery Center, Pasadena, California, United States
🇺🇸Lotus Clinical Research, LLC, Pasadena, California, United States
Histological and Microbiological Evaluation of Late Occurring Nodules With Hyaluronic Acid Dermal Fillers
- First Posted Date
- 2018-02-08
- Last Posted Date
- 2021-08-06
- Lead Sponsor
- Allergan
- Target Recruit Count
- 17
- Registration Number
- NCT03425721
- Locations
- 🇺🇸
Assure Surgical, P.C., New York, New York, United States
🇺🇸Skin Care and Laser Physicians (SCLP) of Beverly Hills, West Hollywood, California, United States
Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02
- Conditions
- Interventions
- First Posted Date
- 2018-02-08
- Last Posted Date
- 2021-08-06
- Lead Sponsor
- Allergan
- Target Recruit Count
- 311
- Registration Number
- NCT03426345
- Locations
- 🇺🇸
Atlanta Diabetes Associates, Atlanta, Georgia, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸The Ohio State University, Wexner Medical Center, Columbus, Ohio, United States
Sequential Treatment With BELKYRA® Then Juvéderm® VOLUMA™ With Lidocaine for Overall Improvement in Jawline Contour
- Conditions
- Interventions
- First Posted Date
- 2018-02-07
- Last Posted Date
- 2020-12-31
- Lead Sponsor
- Allergan
- Target Recruit Count
- 58
- Registration Number
- NCT03425253
- Locations
- 🇦🇺
Living Art, East Melbourne, Victoria, Australia
🇦🇺Darlinghurst Dermatology, Darlinghurst, New South Wales, Australia
🇦🇺Dermatology Institute of Victoria, South Yarra, Victoria, Australia
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03
- Conditions
- Interventions
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2021-12-22
- Lead Sponsor
- Allergan
- Target Recruit Count
- 467
- Registration Number
- NCT03420781
- Locations
- 🇺🇸
Gastroenterology Associates of Fairfield County, P.C., Bridgeport, Connecticut, United States
🇺🇸Applied Research Center of Arkansas, Little Rock, Arkansas, United States
🇺🇸Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States
A Safety and Effectiveness of VOLBELLA XC Hyaluronic Acid (HA) Injectable Gel to Correct Infraorbital Hollowing
- Conditions
- Interventions
- First Posted Date
- 2018-02-01
- Last Posted Date
- 2021-11-15
- Lead Sponsor
- Allergan
- Target Recruit Count
- 163
- Registration Number
- NCT03418545
- Locations
- 🇺🇸
Steve Yoelin MD Medical Associate, Inc., Newport Beach, California, United States
🇺🇸Cosmetic Laser Dermatology, San Diego, California, United States
🇺🇸Facesplus, Inc., San Diego, California, United States
Physiopathologic Aspects and Quality of Life in Participants With Eye Dark Circles
- Conditions
- Interventions
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- Allergan
- Target Recruit Count
- 44
- Registration Number
- NCT03400202
- Locations
- 🇺🇸
SkinMedica Clinical Research and Innovation Center, Irvine, California, United States
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04
- Conditions
- Interventions
- First Posted Date
- 2017-12-26
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- Allergan
- Target Recruit Count
- 450
- Registration Number
- NCT03383146
- Locations
- 🇺🇸
Atlanta Diabetes Associates, Atlanta, Georgia, United States
🇺🇸Endocrinology Research Associates, Inc., Columbus, Ohio, United States
🇺🇸Texas Clinical Research Institute, LLC, Arlington, Texas, United States
Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2018-01-11
- Lead Sponsor
- Allergan
- Target Recruit Count
- 16
- Registration Number
- NCT03376841
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Clinical Pharmacology of Miami, Miami, Florida, United States